A share price of Harmony Biosciences Holdings Inc [HRMY] is currently trading at $41.49, up 16.06%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HRMY shares have gain 19.02% over the last week, with a monthly amount glided 3.73%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, UBS started tracking the stock with Buy rating on September 10, 2024, and set its price target to $56. On June 21, 2024, Citigroup initiated with a Buy rating and assigned a price target of $48 on the stock. BofA Securities downgraded its rating to a Underperform but stick to its price target of $30 on January 02, 2024. Goldman downgraded its rating to a Sell and reduced its price target to $31 on September 25, 2023. Berenberg started tracking with a Buy rating for this stock on September 07, 2023, and assigned it a price target of $59. In a note dated April 20, 2023, BofA Securities initiated an Neutral rating and provided a target price of $35 on this stock.
Harmony Biosciences Holdings Inc experienced fluctuations in its stock price throughout the past year between $19.03 and $40.60. Currently, Wall Street analysts expect the stock to reach $52.33 within the next 12 months. Harmony Biosciences Holdings Inc [NASDAQ: HRMY] shares were valued at $41.49 at the most recent close of the market. An investor can expect a potential return of 26.13% based on the average HRMY price forecast.
Analyzing the HRMY fundamentals
Trailing Twelve Months sales for Harmony Biosciences Holdings Inc [NASDAQ:HRMY] were 656.11M which represents 28.76% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.18%. To continue investigating profitability, this company’s Return on Assets is posted at 0.13, Equity is 0.23 and Total Capital is 0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.31.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 37.94 points at the first support level, and at 34.40 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.32, and for the 2nd resistance point, it is at 45.16.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Harmony Biosciences Holdings Inc [NASDAQ:HRMY] is 3.13. Further, the Quick Ratio stands at 3.09, while the Cash Ratio is 2.4. Considering the valuation of this stock, the price to sales ratio is 3.59, the price to book ratio is 4.38 and price to earnings (TTM) ratio is 21.25.
Transactions by insiders
Recent insider trading involved JEFFREY G DIERKS, Officer, that happened on Oct 29 ’24 when 21496.0 shares were purchased. Officer, JEFFREY G DIERKS completed a deal on Oct 03 ’24 to buy 14961.0 shares. Meanwhile, CHIEF COMMERCIAL OFFICER Dierks Jeffrey sold 400.0 shares on Oct 01 ’24.
